Top

Published in:

01-09-2015 | Breast Oncology

Bilateral Risk-Reduction Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Meta-analysis

Authors: Francesca De Felice, MD, Claudia Marchetti, MD, Angela Musella, MD, Innocenza Palaia, PhD, Giorgia Perniola, PhD, Daniela Musio, MD, Ludovico Muzii, PhD, Vincenzo Tombolini, MD, Pierluigi Benedetti Panici, MD

Published in: Annals of Surgical Oncology | Issue 9/2015

Abstract

Background

Women with BRCA1 and BRCA2 mutations have substantially elevated risk of developing breast cancer. The aim of this study was to clarify the role of bilateral risk-reducing mastectomy (BRRM) in reducing breast cancer risk in women carriers of BRCA1 and BRCA2 mutations.

Methods

The Pubmed, MEDLINE and Scopus databases were searched to retrieve articles written in the English language. Two investigators independently extracted the characteristics and results of the selected studies. Only prospective trials with available absolute numbers of breast cancer and death events were included. Pooled hazard ratio (HR) with 95 % confidence interval (CI) was calculated using fixed or random effects model.

Results

Meta-analysis of four prospective studies, including 2635 patients, demonstrated a significant risk reduction of breast cancer incidence in BRCA1 and BRCA2 mutation carriers receiving BRRM (HR 0.07; 95 % CI 0.01–0.44; p = 0.004). Among patients without previous risk-reducing salpingo-oophorectomy, a significant benefit was similarly recorded (HR 0.06; 95 % CI 0.01–0.41; p = 0.005).

Conclusions

Performing BRRM may lead to highly significant risk reduction of breast cancer in BRCA1 and BRCA2 mutation carriers. These data allow clinicians to discuss more in-depth with patients all the available options in order to design better management strategies.

Nelson HD, Huffman LH, Fu R, Harris EL; U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143(5):362–79.PubMedCrossRef

National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. NCCN Practice Guidelines, 2014. Available at: http://www.nccn.org/professionals/physician_gls/recently_updated.asp.

Marchetti C, De Felice F, Palaia I, et al. Prophylactic salpingo-oophorectomy: a meta-analysis on ovarian cancer risk and all cause mortality. BMC Womens Health. 2014;14(1):150.PubMedCentralPubMedCrossRef

Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75–89.PubMedCrossRef

Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol. 2013;24(8):2029–35.PubMedCrossRef

Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159–64.PubMedCrossRef

Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75.PubMedCentralPubMedCrossRef

Skytte AB, Crüger D, Gerster M, et al. Breast cancer after bilateral risk-reducing mastectomy. Clin Genet. 2011;79(5):431–7.PubMedCrossRef

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedCentralPubMedCrossRef

10.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCentralPubMedCrossRef

11.

Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCentralPubMedCrossRef

12.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1008–101.CrossRef

13.

Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org.

14.

Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77–84.PubMedCrossRef

15.

Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80–7.PubMedCentralPubMedCrossRef

16.

Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91(17):1475–9.PubMedCrossRef

17.

Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23(30):7491–6.PubMedCrossRef

18.

King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–6.PubMedCrossRef

19.

Juthe RH, Zaharchuk A, Wang C. Celebrity disclosures and information seeking: the case of Angelina Jolie. Genet Med. 2014. doi:10.1038/gim.2014.141.

20.

Marchetti C, Iadarola R, Palaia I, Di Donato V, Perniola G, Muzii L, et al. Hormone therapy in oophorectomized BRCA1/2 mutation carriers. Menopause. 2014;21(7):763–8.PubMedCrossRef

21.

Del Corral GA, Wes AM, Fischer JP, Serletti JM, Wu LC. Outcomes and cost analysis in high-risk patients undergoing simultaneous free flap breast reconstruction and gynecologic procedures. Ann Plast Surg. 2014. doi:10.1097/SAP.0000000000000156.

22.

Hooker GW, King L, Vanhusen L, et al. Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers. Hered Cancer Clin Pract. 2014;12(1):9.PubMedCentralPubMedCrossRef

Title: Bilateral Risk-Reduction Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Meta-analysis
Authors: Francesca De Felice, MD
Claudia Marchetti, MD
Angela Musella, MD
Innocenza Palaia, PhD
Giorgia Perniola, PhD
Daniela Musio, MD
Ludovico Muzii, PhD
Vincenzo Tombolini, MD
Pierluigi Benedetti Panici, MD
Publication date: 01-09-2015
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 9/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-015-4532-1

At a glance: The STEP trials

Springer Medicine

Bilateral Risk-Reduction Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Meta-analysis

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2015

Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)

The Use of Radiation Therapy in Localized High-Grade Soft Tissue Sarcoma and Potential Impact on Survival

Time Trends in the Incidence and Treatment of Extra-Abdominal and Abdominal Aggressive Fibromatosis: A Population-Based Study

Clinical Presentation of Patients with a Thyroid Follicular Neoplasm: Are there Preoperative Predictors of Malignancy?

Plate Exposure After Anterolateral Thigh Free-Flap Reconstruction in Head and Neck Cancer Patients With Composite Mandibular Defects

Tumoral CD10 Expression Correlates with Aggressive Histology and Prognosis in Patients with Malignant Pleural Mesothelioma